Cardiac Stem Cell Population With CD105 Selection for Low-Inflammation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cardiac stem cells used for regenerative medicine have limitations in therapeutic efficacy and may cause side effects during transplantation, necessitating the development of improved stem cells with enhanced production abilities and immunoregulatory functions.
Innovation Solution
A cell population comprising human-derived cardiac stem cells with a high proportion of CD105 expression and no αMHC gene, exhibiting enhanced ADM, MMP1, and HGF production abilities, along with specific surface antigen profiles, is developed to improve therapeutic efficacy and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cardiac stem cells are used for transplantation, then regenerative treatment for cardiac diseases can be achieved, but therapeutic efficacy is limited and side effects may occur
Solution Approach 1:
The patent applies parameter changes by selecting and expanding cardiac stem cells with specific surface antigen expression profiles (CD105≥70%, CD90≥30%, CD45≤10%, CD34≤10%). This parameter-based selection optimizes the cellular composition to enhance therapeutic efficacy while minimizing side effects through controlled differentiation potential and reduced immunogenicity.
Solution Approach 2:
The patent implements local quality by creating a heterogeneous cell population with distinct functional subpopulations. The cell population includes cells with different surface antigen profiles that contribute to various functions: some cells differentiate into cardiomyocytes while others provide paracrine support, creating localized functional zones within the transplant that address multiple therapeutic needs simultaneously.
2Productivity
If stem cells are selected based on sphere formation in suspension culture, then pluripotent stem cells can be obtained, but production ability and immunoregulatory function are insufficient
Solution Approach 1:
The patent fundamentally changes the selection parameters from morphology-based (sphere formation) to surface antigen expression-based selection. By using flow cytometry to identify cells with specific antigen profiles (CD105≥70%, CD90≥30%, CD45≤10%, CD34≤10%), the method enriches for cells with enhanced production ability and immunoregulatory function, overcoming the limitations of conventional sphere-based selection.
Solution Approach 2:
The patent replaces the mechanical/morphological selection method (sphere formation in suspension) with a biochemical identification method (surface antigen expression analysis via flow cytometry). This substitution enables more precise selection of cells based on molecular markers that correlate with desired functional properties, thereby improving both productivity and immunoregulatory ability.
Data Source
Figure 1
Figure 2A~2H
Figure 3A~3H
AI summary
By expressing specific factors in cardiac stem cells, it was found that their ADM production ability, MMP1 production ability, and/or HGF production ability could be enhanced. Additionally, it was found that such cardiac stem cells exhibit excellent immune-regulatory and/or anti-inflammatory capabilities. Therefore, a cell population comprising such cardiac stem cells can be provided.